Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Dividends Paid - Preferred Dividends Paid - Preferred Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Lifecore Biomedical, Inc. \De\ (LFCR) Net Cash Flow (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Net Cash Flow over the past 16 years, most recently at $2.8 million for Q2 2025.

For Q2 2025, Net Cash Flow fell 47.15% year-over-year to $2.8 million; the TTM value through May 2025 reached -$197000.0, up 98.15%, while the annual FY2025 figure was -$197000.0, 98.15% up from the prior year.
Net Cash Flow for Q2 2025 was $2.8 million at Lifecore Biomedical, Inc. \De\, up from -$4.0 million in the prior quarter.
Over five years, Net Cash Flow peaked at $16.1 million in Q2 2023 and troughed at -$16.4 million in Q1 2021.
A 5-year average of -$574166.7 and a median of -$179500.0 in 2022 define the central range for Net Cash Flow.
Biggest five-year swings in Net Cash Flow: soared 7749.76% in 2023 and later plummeted 2628.38% in 2025.
Year by year, Net Cash Flow stood at -$356000.0 in 2021, then soared by 832.58% to $2.6 million in 2022, then crashed by 307.86% to -$5.4 million in 2023, then soared by 172.59% to $3.9 million in 2024, then dropped by 27.62% to $2.8 million in 2025.
Business Quant data shows Net Cash Flow for LFCR at $2.8 million in Q2 2025, -$4.0 million in Q1 2025, and $3.9 million in Q4 2024.